Company Overview
TScan Therapeutics, Inc. operates as a clinical-stage biotechnology company dedicated to developing T cell receptor-engineered T cell (TCR-T) therapies specifically for treating cancer patients within the United States. The firm functions within the broader Healthcare sector and the specialized Biotechnology industry, positioning itself to address high-value therapeutic needs through innovative cell engineering. The company's financial scale is characterized by a market capitalization of $56.25M and annual revenue of $10.32M, supported by an organizational structure comprising 142 employees. These valuation and revenue figures indicate that TScan Therapeutics is a small-cap entity with a relatively modest revenue base, typical for early-stage biotechnology firms that prioritize clinical development over immediate profitability.
Financial Health
The company reported revenue of $10.32M over the trailing twelve months, yet this generated a net income of -$129,766,000 and an EBITDA of -$130,947,000, revealing a cost structure where expenses significantly exceed operational revenue. The resulting free cash flow of -$97,246,752 underscores a capital-intensive business model where cash burn is substantial, limiting immediate financial flexibility for expansion without external funding. Marginal performance is stark across all metrics, with a gross margin of 0.0%, an operating margin of -851.5%, and a profit margin of 0.0%, indicating that the company is not yet generating profit from its core operations or sales. On the balance sheet, the company holds $152.41M in cash against $94.14M in debt, resulting in a debt-to-equity ratio of 76.46, which suggests a leveraged position despite the high absolute cash balance. Liquidity is robust in the short term, evidenced by a current ratio of 8.41, which implies the company possesses ample current assets to cover its short-term obligations. Return metrics reflect the developmental stage, with a return on equity of -71.3% and a return on assets of -27.9%, demonstrating that management has not yet achieved positive returns on the capital invested in the business.
Valuation Assessment
Valuation metrics for TScan Therapeutics reflect its lack of profitability, with a trailing P/E ratio of N/A and a forward P/E of -1.29, implying that traditional earnings-based valuation models are not currently applicable due to negative earnings projections. The price-to-book ratio stands at 0.46, indicating that the market values the company's equity at a significant discount relative to its book value, a common characteristic for distressed or pre-revenue biotech firms. Alternative valuation measures such as the price-to-sales ratio of 5.45 and an EV/EBITDA of 0.01 provide context for investors analyzing the company based on revenue multiples rather than earnings power. Price action over the last year has seen the stock trade between a 52-week high of $2.57 and a 52-week low of $0.88, placing the current valuation within a wide historical range that reflects high market volatility. The stock exhibits a beta of 1.03, suggesting that its price volatility moves in tandem with, or slightly more than, the broader market, making it a non-defensive holding for portfolios seeking exposure to high-risk biotechnology innovation.
Growth & Income
Revenue growth for the year-over-year period reached 286.0%, while earnings growth is listed as N/A, illustrating a scenario where revenue expansion is occurring while profitability remains absent due to high clinical and operational costs. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, as evidenced by the 0.0% payout ratio, meaning all available cash resources are reinvested into research and development rather than returned to shareholders. This reinvestment strategy is standard for clinical-stage companies that must allocate capital to advance their lead product, TSC-101, through clinical trials to achieve commercial approval. The overall growth and income profile is defined by aggressive top-line expansion coupled with a complete lack of current earnings or dividend income, creating a high-risk, high-potential reward dynamic typical of the biotechnology sector.